The U.S. hip arthroscopy market is going through a period of rapid expansion, growing faster than any other major orthopedic sports medicine segment and redefining current approaches to hip preservation. Fueled by technological advancements, shifting patient demographics, and a deeper clinical understanding of hip-related conditions, procedure growth is occurring at nearly twice the rate of mature arthroscopic categories such as shoulder labrum repair, signaling a structural shift in how hip pathology is diagnosed, treated, and managed.

From Niche Technique to Mainstream Intervention

Once considered a technically demanding procedure with narrow indications, hip arthroscopy has evolved into a widely accepted treatment option for a broad range of hip disorders. Procedure volumes continue to rise sharply each year, far outpacing growth in the overall arthroscopy market, which is expected to expand at a comparatively modest pace.

The single most important driver behind this growth is the increased recognition and diagnosis of femoroacetabular impingement (FAI), a condition in which abnormal bone formation along the hip joint leads to friction and pain during movement. Historically overlooked or misdiagnosed as another musculoskeletal issue, FAI is now widely considered a leading cause of hip pain and early joint degeneration, particularly among younger, active patients.

Advances in imaging and a deeper clinical understanding have now made FAI one of the leading indications for hip arthroscopy. As a result, surgeons are intervening earlier in the disease course, often with the goal of delaying or avoiding total hip replacement. This shift has meaningful downstream implications for procedure volumes, device utilization, and long-term patient management strategies.

Importantly, awareness of FAI has expanded beyond orthopedic specialists. Primary care physicians, athletic trainers, and physical therapists are increasingly adept at identifying symptoms and directing patients to surgical consultation. Patients themselves are also more informed, entering care pathways with a stronger preference for joint-preserving, minimally invasive options.

The Accelerating Shift to Ambulatory Surgery Centers

One of the most significant forces reshaping the hip arthroscopy market is the rapid transition of procedures from traditional hospital operating rooms to ambulatory surgery centers (ASCs). This shift reflects both a fundamental change in the orthopedic business model and growing confidence in the safety, efficiency, and effectiveness of outpatient surgical care.

Today, hospital and ASC procedure volumes are nearly equal; however, within the next few years, ASCs are expected to surpass hospitals in the number of hip arthroscopies performed, with the gap widening steadily through the forecast period. ASC procedure volumes are increasing at a much faster annual rate than those performed in hospitals, marking a complete reversal from trends observed just a few years ago.

Several factors underpin this shift. Technological advancements and refinements in anesthesia and surgical techniques have made hip arthroscopy well-suited for outpatient settings, allowing most patients to return home on the same day. ASCs deliver substantial cost savings compared to hospital-based care and often house highly specialized surgical teams, leading to improved outcomes and higher patient satisfaction. These advantages reinforce a self-sustaining cycle of quality, efficiency, and adoption.

The financial incentives align across stakeholders in the healthcare ecosystem. Providers benefit from streamlined operations, lower overhead, and increased patient throughput. Payers are motivated by the lower costs associated with ASC procedures, while patients enjoy shorter wait times, reduced out-of-pocket expenses, and the convenience of same-day discharge. In contrast, office-based surgical settings are seeing a decline in case volumes, indicating market consolidation around established ASC and hospital networks.

Product Market Dynamics: Innovation Driving Growth

The hip arthroscopy device market is expanding across all major product categories, although growth rates vary significantly by segment, depending on their level of technological maturity and adoption.

Banana blades and hip access kits are at the forefront of this expansion. Banana blades (precision-cutting instruments designed specifically for the hip joint’s distinct anatomy) are seeing exceptional growth fueled by rising procedure volumes and modest price appreciation, a rare combination in the medical device sector. Likewise, hip access kits are benefiting from consistent procedural demand, their single-use nature, and a growing need for advanced access systems in increasingly complex cases.

Radiofrequency (RF) probes remain the largest product segment by revenue. A notable shift within this category is the faster growth of static RF probes relative to articulating designs. As surgeon skill levels have increased and static probe performance has improved, the incremental value of articulation has diminished in routine cases. Static probes now offer comparable clinical performance at a lower cost, driving their market dominance.

Other market segments like suture anchors continue to benefit from the overall rise in hip arthroscopy volumes, though intensified competition is exerting moderate downward pressure on pricing. Allografts, while relatively small, remain crucial for complex reconstructive procedures and represent the biological frontier of hip preservation. Meanwhile, disposable kits are seeing limited market value growth despite strong gains in unit sales, as significant price compression, driven by economies of scale and aggressive ASC purchasing strategies, continues to reshape this increasingly commoditized product category.

Competitive Landscape: A Three-Way Race

The U.S. hip arthroscopy market is highly concentrated, with three companies, Arthrex, Stryker, and Smith & Nephew, dominating roughly 80% of the total market share by revenue.

Arthrex leads the field, capturing about 30% of total market spending through its broad participation across five of the six major product categories. The company maintains clear leadership in allografts, disposable kits, and radiofrequency probes, enabling it to offer comprehensive solutions and capitalize on healthcare facilities’ preference for vendor consolidation.

Stryker follows closely, supported by strong positions in banana blades and hip access kits. Its strategy centers on premium product lines and fully integrated systems. With its dominance in the rapidly expanding banana blade segment, Stryker is well-positioned to sustain and potentially expand its market share in the coming years.

Smith & Nephew holds approximately 20% of the market, driven by solid sales in hip access kits, disposable kits, and suture anchors. However, its limited presence in banana blades and lack of an allograft offering leave it exposed to competitive pressures in key growth areas. DePuy Synthes and Zimmer Biomet maintain smaller but notable shares, while CONMED competes primarily as a value-oriented alternative. The remainder of the market is fragmented among niche and emerging manufacturers.

Overall, competitive pressures point toward continued market consolidation. The top three players possess the scale and resources to invest heavily in research and development, surgeon training, and clinical education, which are all essential for success in a technically demanding field. Smaller manufacturers will need to identify specialized niches or face the likelihood of acquisition or market exit.

Looking Ahead

Sustained market growth will depend on continued innovation across multiple fronts. The next generation of hip arthroscopy instruments will need to enhance procedural accessibility while driving measurable improvements in clinical outcomes. Emerging technologies, such as advanced navigation systems, robotic assistance, and next-generation visualization tools, have the potential to extend adoption beyond high-volume specialty centers and into a broader base of orthopedic practices.

Future growth opportunities also lie in expanding the range of indications beyond femoroacetabular impingement (FAI), including applications in synovial disorders, early-stage osteoarthritis, and sports-related injuries. Meanwhile, the shift toward value-based care models will increasingly influence purchasing behavior, rewarding manufacturers that can demonstrate superior total cost-of-care performance through improved efficiency, durability, and patient outcomes.

Conclusion

The hip arthroscopy market stands out as one of the most dynamic and promising segments within orthopedic sports medicine, but sustaining this trajectory will depend on continued innovation, strong clinical evidence, and alignment with value-driven care models. Advances in instrumentation, visualization, and procedural workflow are expected to expand adoption beyond high-volume specialty centers while supporting the ongoing shift of cases into ambulatory surgery centers.

As procedure volumes rise and move into lower-cost outpatient settings, payers will increasingly focus on long-term outcomes and total cost of care. Comparative clinical data demonstrating the durability and economic value of arthroscopic intervention, particularly relative to conservative management, will be critical for maintaining reimbursement and expanding indications beyond femoroacetabular impingement.

Overall, hip arthroscopy has transitioned from a niche technique into a core joint-preservation strategy. For manufacturers, success will depend on delivering integrated, cost-effective solutions optimized for ASC environments. For providers, the procedure offers a compelling combination of clinical benefit, operational efficiency, and sustainable growth, positioning hip arthroscopy as a key driver of the next phase of minimally invasive orthopedic care.

Nathaniel Bool is an analyst team lead at iData Research. He develops and composes syndicated research projects regarding the medical device industry, publishing the U.S. Orthopedic Soft Tissue Repair report series.

Kamran Zamanian, Ph.D., is CEO and founding partner of iData Research. He has spent over 20 years working in the market research industry with a dedication to the study of medical devices used in the health of patients all over the globe.